267 related articles for article (PubMed ID: 28389531)
21. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
22. Mithramycin A Inhibits Colorectal Cancer Growth by Targeting Cancer Stem Cells.
Quarni W; Dutta R; Green R; Katiri S; Patel B; Mohapatra SS; Mohapatra S
Sci Rep; 2019 Oct; 9(1):15202. PubMed ID: 31645574
[TBL] [Abstract][Full Text] [Related]
23. Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.
De Angelis ML; Zeuner A; Policicchio E; Russo G; Bruselles A; Signore M; Vitale S; De Luca G; Pilozzi E; Boe A; Stassi G; Ricci-Vitiani L; Amoreo CA; Pagliuca A; Francescangeli F; Tartaglia M; De Maria R; Baiocchi M
Stem Cells Transl Med; 2016 Apr; 5(4):511-23. PubMed ID: 26956206
[TBL] [Abstract][Full Text] [Related]
24. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.
Solomon H; Dinowitz N; Pateras IS; Cooks T; Shetzer Y; Molchadsky A; Charni M; Rabani S; Koifman G; Tarcic O; Porat Z; Kogan-Sakin I; Goldfinger N; Oren M; Harris CC; Gorgoulis VG; Rotter V
Oncogene; 2018 Mar; 37(12):1669-1684. PubMed ID: 29343849
[TBL] [Abstract][Full Text] [Related]
25. Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.
Angius G; Tomao S; Stati V; Vici P; Bianco V; Tomao F
Cancer Chemother Pharmacol; 2020 Jan; 85(1):9-20. PubMed ID: 31512029
[TBL] [Abstract][Full Text] [Related]
26. Identification of a checkpoint modulator with synthetic lethality to p53 mutants.
Harada N; Watanabe Y; Yoshimura Y; Sakumoto H; Makishima F; Tsuchiya M; Nakanishi K; Nakanishi M; Aoki Y
Anticancer Drugs; 2011 Nov; 22(10):986-94. PubMed ID: 21822123
[TBL] [Abstract][Full Text] [Related]
27. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
28. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
29. The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition.
Mattiello L; Soliman Abdel Rehim S; Musella M; Sistigu A; Guarracino A; Vitale S; Corradi F; Galassi C; Sperati F; Manic G; De Maria R; Vitale I
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921638
[TBL] [Abstract][Full Text] [Related]
30. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Wang WT; Catto JW; Meuth M
Oncogene; 2015 May; 34(22):2887-96. PubMed ID: 25043304
[TBL] [Abstract][Full Text] [Related]
31. Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors.
Hubackova S; Davidova E; Boukalova S; Kovarova J; Bajzikova M; Coelho A; Terp MG; Ditzel HJ; Rohlena J; Neuzil J
Cell Death Dis; 2020 Feb; 11(2):110. PubMed ID: 32034120
[TBL] [Abstract][Full Text] [Related]
32. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
33. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
34. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
35. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.
Veschi V; Mangiapane LR; Nicotra A; Di Franco S; Scavo E; Apuzzo T; Sardina DS; Fiori M; Benfante A; Colorito ML; Cocorullo G; Giuliante F; Cipolla C; Pistone G; Bongiorno MR; Rizzo A; Tate CM; Wu X; Rowlinson S; Stancato LF; Todaro M; De Maria R; Stassi G
Oncogene; 2020 Jan; 39(5):987-1003. PubMed ID: 31591478
[TBL] [Abstract][Full Text] [Related]
36. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.
Mennonna D; Maccalli C; Romano MC; Garavaglia C; Capocefalo F; Bordoni R; Severgnini M; De Bellis G; Sidney J; Sette A; Gori A; Longhi R; Braga M; Ghirardelli L; Baldari L; Orsenigo E; Albarello L; Zino E; Fleischhauer K; Mazzola G; Ferrero N; Amoroso A; Casorati G; Parmiani G; Dellabona P
Gut; 2017 Mar; 66(3):454-463. PubMed ID: 26681737
[TBL] [Abstract][Full Text] [Related]
37. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
[TBL] [Abstract][Full Text] [Related]
38. Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.
Herůdková J; Paruch K; Khirsariya P; Souček K; Krkoška M; Vondálová Blanářová O; Sova P; Kozubík A; Hyršlová Vaculová A
Neoplasia; 2017 Oct; 19(10):830-841. PubMed ID: 28888100
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
40. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
Toden S; Tran HM; Tovar-Camargo OA; Okugawa Y; Goel A
Oncotarget; 2016 Mar; 7(13):16158-71. PubMed ID: 26930714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]